ClinicalTrials.gg
CompletedNCT01018979Updated May 11, 2021Results posted

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

A Phase 2 interventional study of TG-0054 (2.24 mg/kg) and TG-0054 (3.14 mg/kg) in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by GPCR Therapeutics, Inc.. Completed at 6 sites in Taiwan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 71 studies in Multiple Myeloma with a site in Taiwan — 19 open to participants now, 33 under way, 23 of them phase 3. Multiple Myeloma · Taiwan.

Enrollment
60th of 64
19 · median 431
Started
2010
with 1 other
Phase 2
7 of 71
1 open now
Registered
3rd of 71
by date

Among the 71 studies in Multiple Myeloma with a site in Taiwan, this one is the 60th largest by enrollment of the 64 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 3rd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

19 of the 71 studies in Multiple Myeloma with a site in Taiwan are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Multiple Myeloma with a site in Taiwan, or all of them as a file.
02

Study summary

A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.

03

Conditions studied

  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Hodgkin Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 to 70 years of age inclusive
  • Patients with confirmed pathology diagnosis of MM, NHL or HD
  • Potential candidate for stem cell transplantation at Investigator's discretion
  • ≦ 2 prior regimens of cytotoxic chemotherapy (rituximab, thalidomide, and bortezomib will not be considered as cytotoxic chemotherapy)
  • > 4 weeks since last cycle of chemotherapy prior to the study drug administration
  • Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment
  • (ECOG) performance status of 0 or 1
  • Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion
  • White blood cell (WBC) count ≧ 3.0 x 109/L on screening laboratory assessments
  • ≧ 1.5 x 109/L on screening laboratory assessments
  • count ≧ 100 x 109/L on screening laboratory assessments
  • Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments
  • (AST), alanine aminotransferase (ALT), and total \< 2 x (ULN) on screening laboratory assessments
  • Negative for (HIV)
  • Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion
  • For females, one of the following criteria must be fulfilled:

    1. At least one year , or
    2. Surgically sterile, or
    3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of throughout the study
  • Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054
  • Able to provide the signed

Exclusion criteria

Exclusion Criteria:

  • Received radiation therapy around the pelvic or spinal area within 6 months prior to the study drug administration
  • >10% bone marrow involvement of lymphoma in NHL patients
  • Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within 4 apheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)]
  • Patients who have undergone previous stem cell transplantation procedure
  • Received G-CSF within 2 weeks prior to the study drug administration
  • History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin
  • History of other hematologic disorders including bleeding or thromboembolic disease
  • History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, , stroke or (COPD) patients hospitalized more than two times a year due to underlying disease
  • Diagnosis of sickle cell anemia or documented sickle cell trait
  • Uncontrollable with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion
  • Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing
  • Pregnant or breast-feeding
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
  • Received any other drug within 1 month before entering the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    TG-0054 (2.24 mg/kg)

    TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

    Drug: TG-0054 (2.24 mg/kg)

  • Experimental
    TG-0054 (3.14 mg/kg)

    TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

    Drug: TG-0054 (3.14 mg/kg)

Interventions

  • DrugTG-0054 (2.24 mg/kg)

    Drug page: BurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

  • DrugTG-0054 (3.14 mg/kg)

    Drug page: BurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).

    Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.

    Time frame: 1 week

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  2. Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.

    Time frame: Baseline, 3 hours and 6 hours after infusion

  3. Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  4. Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  5. Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  6. The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  7. The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  8. Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  9. Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  10. Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

    Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

    Time frame: 36 hrs after infusion

  11. Circulating CD34+ Cell Counts in Peripheral Blood.

    Time frame: Baseline, 3 hours and 6 hours after infusion

07

Results

Posted Jan 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Started713
Received at least one dose712
Completed43
Not completed310
Withdrew: Peak cd34+ cell count in pb < 10 cell/ul39
Withdrew: Not received at least one dose01

Outcome measures

PrimaryNumber of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).

Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.

Time frame:
1 week
Reported as:
Number · participants
Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).
participantsTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
MM11
NHL10
HD00
SecondaryMaximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
ng/mLTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.20971 ± 699529665 ± 18583
SecondaryFold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.
Time frame:
Baseline, 3 hours and 6 hours after infusion
Reported as:
Mean · fold
Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.
foldMultiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD)All Patients
Fold increase (3 hours after infusion)7.0 ± 5.96.1 ± 6.16.4 ± 5.9
Fold increase (6 hours after infusion)7.8 ± 7.27.8 ± 10.47.8 ± 9.1
Fold increase (Maximum increase)9.3 ± 7.510.3 ± 8.910.0 ± 8.4
Statistical analysis
  • Multiple Myeloma (MM) · t-test, 2 sided · p = 0.023 (P values less than 0.05 are considered statistically significant in this study.)
  • Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD) · t-test, 2 sided · p = 0.038 (P values less than 0.05 are considered statistically significant in this study.)
SecondaryTime at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · hr
Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
hrTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.0.25 ± 00.25 ± 0
SecondaryTerminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · hr
Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
hrTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.4.65 ± 0.44.28 ± 0.6
SecondaryTerminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · 1/hr
Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
1/hrTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.0.15 ± 0.010.16 ± 0.02
SecondaryThe Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · hr*ng/mL
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.
hr*ng/mLTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.43610 ± 703455814 ± 12153
SecondaryThe Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · hr*ng/mL
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.
hr*ng/mLTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.43713 ± 703955920 ± 12170
SecondaryClearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · mL/ hr/kg
Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
mL/ hr/kgTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.52.5 ± 9.458.6 ± 13.0
SecondaryVolume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · mL/kg
Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
mL/kgTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.351 ± 62366 ± 112
SecondaryVolume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.

Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.

Time frame:
36 hrs after infusion
Reported as:
Mean · mL/kg
Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
mL/kgTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.179 ± 64193 ± 76
SecondaryCirculating CD34+ Cell Counts in Peripheral Blood.
Time frame:
Baseline, 3 hours and 6 hours after infusion
Reported as:
Mean · cells/μL
Circulating CD34+ Cell Counts in Peripheral Blood.
cells/μLMultiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD)All Patients
PB CD34+ count (Baseline)1.0 ± 0.70.9 ± 0.51.0 ± 0.6
PB CD34+ count (3 hours after infusion)5.7 ± 4.04.0 ± 2.14.6 ± 2.9
PB CD34+ count (6 hours after infusion)6.3 ± 3.94.3 ± 2.75.1 ± 3.3
PB CD34+ count (Maximum increase)7.8 ± 4.45.2 ± 3.76.5 ± 4.1

Adverse events

Collected over The whole study period, from Visit 1 (screening, day -14) to Visit 9 (7 days after the last dose). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TG-0054 (2.24 mg/kg)—2/7 (28.6%)6/7 (85.7%)
TG-0054 (3.14 mg/kg)—6/12 (50%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
ADMISSION FOR PREPARATION OF PERIPHERAL BLOOD STEM CELL HARVESTSurgical and medical procedures0/73/12
HOSPITALIZATION FOR BONE MARROW TRANSPLANTATIONSurgical and medical procedures1/70/12
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATIONSurgical and medical procedures1/70/12
AUTOLOGOUS STEM CELL TRANSPLANTSurgical and medical procedures0/71/12
TREATMENT OF NON-HODGKIN LYMPHOMASurgical and medical procedures0/71/12
PEIPHERAL BLOOD STEM CELL HARVESTSurgical and medical procedures0/71/12
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)
DIZZINESSNervous system disorders2/71/12
LEUKOCYTOSISBlood and lymphatic system disorders2/72/12
ABDOMINAL PAINGastrointestinal disorders1/70/12
ABNORMAL DATA OF INCREASE BILIRUBINInvestigations1/70/12
CHEST TIGHTNESSRespiratory, thoracic and mediastinal disorders1/70/12
CLONIC OF RIGHT KNEENervous system disorders1/70/12
DIARRHEAGastrointestinal disorders1/71/12
HYPERCALCEMIAMetabolism and nutrition disorders1/70/12
HYPOCALCIUMMetabolism and nutrition disorders1/70/12
HYPOKALEMIAMetabolism and nutrition disorders1/71/12

Baseline characteristics

19 subjects met all eligibility criteria and received at least one dose of TG-0054.

Age, Continuous
Age, Continuous(years)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Mean47.3 ± 15.552.4 ± 9.350.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Female4711
Male358
Height
Height(centimeters)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Mean162.7 ± 10.1158.7 ± 8.6160.2 ± 9.1
Weight
Weight(kilogram)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Mean67.3 ± 23.160.6 ± 10.263.1 ± 15.9
Body Mass Index
Body Mass Index(kilogram/ meter^2)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Mean25.1 ± 6.024.0 ± 3.024.4 ± 4.2
Diagnosis
Diagnosis(participants)TG-0054 (2.24 mg/kg)TG-0054 (3.14 mg/kg)Total
Multiple myeloma347
Non-Hodgkin lymphoma3710
Hodgkin disease112
08

Study locations

6 sites
  • Chang-Gung Memorial Hospital Chiayi
    Chiayi, Taiwan
  • Buddist Tzu Chi General Hospital
    Hualien, Taiwan
  • Kaohsiung Medical University Hospital
    Kaohsiung, Taiwan
  • Chang-Gung Memorial Hospital Linkou
    Linkou, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 25, 2009
Start
Feb 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jan 15, 2015
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01018979
Lead sponsor
GPCR Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 25, 2009
Start date
Feb 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jan 15, 2015
Last update
May 11, 2021

Study contacts

Tzeon-Jye Chiou, MD
principal investigator · Taipei Veterans General Hospital, Taiwan
Tso-Fu Wang, MD
principal investigator · Buddist Tzu Chi General Hospital
Sheng-Fung Lin, MD
principal investigator · Kaohsiung Medical University
Chih-Cheng Chen, MD
principal investigator · Chang Gung Memorial Hospital, Chiayi
Po-Nan Wang, MD
principal investigator · Chang Gung Memorial Hospital
Jih-Luh Tang, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Burixafor

Start the discussion